Angiogenesis inhibitors are expected to be used in the therapies of several different cancers-colon, breast, prostate, ovarian, head & neck/esophageal, pancreatic and lung among others.  CTO a small molecule that has comparable effects to AVASTIN in preclinical colon cancer.  It can be given orally.  In addition,  CTO is a synthetic oral inhibitor of calcium influx and has demonstrated anti-invasive and anti-proliferative properties.  Most importantly, it will be cost effective in comparison to comparable biological angiogenesis inhibitors.